Manhattan Psychiatric Center

New Study: Brain Training Reduces Aggressive Behavior in People with Schizophrenia

Retrieved on: 
Tuesday, June 20, 2023
Cognition, Psychiatry, Exercise, Violence, Manhattan Psychiatric Center, Quality of life, Aggression, Research, Attention, History, Social cognition, Medicare, Patient, Risk, SAN, Hearing, Posit Science Corporation, Spectrum, Grammatical mood, Remedy, Social, Memory, Passive-aggressive behavior, Pharmaceutical industry, Schizophrenia

This study used the brain training app, BrainHQ from Posit Science .

Key Points: 
  • This study used the brain training app, BrainHQ from Posit Science .
  • While antipsychotic drugs are routinely used to manage aggression in schizophrenia, their benefits are limited by issues of non-adherence and inadequate treatment response.
  • A number of prior studies in schizophrenia found that BrainHQ exercises improved measures of cognitive function and social cognition in people with Schizophrenia.
  • The researchers hypothesized that a combination of BrainHQ exercises with computerized social cognition exercises might reduce aggressive behavior more than BrainHQ alone.

EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Retrieved on: 
Wednesday, February 22, 2023
XETRA, Manhattan Psychiatric Center, Psychiatry, PANSS, Positive, Safety, Patient, Nathan Kline Institute for Psychiatric Research, CNS, Peripheral nervous system, CET, Psychosis, Congress, TRS, Disease, Clozapine, Schizophrenia International Research Society, European, Headache, Clinical Global Impression, Pharmaceutical industry, Newron Cup, Research

Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.

Key Points: 
  • Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.
  • Further evidence of the progressive benefit over time was evident from the growing proportion of patients rated “very much improved” at one year.
  • These Phase II, open-label data of evenamide in patients with TRS, obtained with blinded raters, are very promising.
  • The company continues its dialogue with industry partners around potential future collaboration opportunities for the development of evenamide.

Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia

Retrieved on: 
Thursday, February 16, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, XETRA, Manhattan Psychiatric Center, Psychiatry, PANSS, Positive, Safety, Patient, Nathan Kline Institute for Psychiatric Research, CNS, Peripheral nervous system, CET, Congress, TRS, Disease, Clozapine, Schizophrenia International Research Society, European, Headache, Clinical Global Impression, Medication, Pharmaceutical industry, Newron Cup

Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.

Key Points: 
  • Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously.
  • These Phase II, open-label data of evenamide in patients with TRS, obtained with blinded raters, are very promising.
  • Newron expects to initiate a potentially pivotal, multinational, randomized, placebo-controlled trial in patients with TRS (study 003) in 2023, as part of its ongoing Phase II/III development plan for evenamide.
  • The company continues its dialogue with industry partners around potential future collaboration opportunities for the development of evenamide.

Laguna Health Recruits Behavioral Change Expert Jeff Rubin as VP of Behavioral Health and Clinical Integration

Retrieved on: 
Thursday, January 20, 2022
Pleasure, Patient, Ward, Hospital, Stroke, Mental health, Organization, CMO, Fatigue, Psychology, VP, Obesity, Health, Anxiety, Manhattan Psychiatric Center, Cigna, Depression, Private practice, Medical device, Medicine, Accolade

DENVER, Jan. 20, 2022 /PRNewswire/ -- Laguna Health , a digital-first home recovery platform, today announced that Dr. Jeff Rubin has joined as VP of Behavioral Health and Clinical Integration.

Key Points: 
  • DENVER, Jan. 20, 2022 /PRNewswire/ -- Laguna Health , a digital-first home recovery platform, today announced that Dr. Jeff Rubin has joined as VP of Behavioral Health and Clinical Integration.
  • At Laguna, Dr. Rubin will oversee all clinical and behavioral health operations and is responsible for codifying the home recovery journey.
  • "Health should be viewed holistically, and having Jeff bring his behavioral health experience to the table is a huge win for the Laguna team.
  • Laguna assures successful post-hospitalization recovery by combining data, digital care tools, and proven behavioral health interventions to radically reduce negative outcomes.